Breast Cancer Clinical Trial
Official title:
Randomized Controlled Trial of Combined Aerobic and Resistance Exercise in Breast Cancer Survivors. The CARE Trial.
Endurance exercise such as walking has been shown to help breast cancer survivors maintain their energy and quality of life while they are receiving chemotherapy, but there have not been any studies on weight training. In this study, the researchers want to determine if a combined program of endurance and weight training exercises is better than a standard amount of endurance exercise or even a higher amount of endurance exercise in breast cancer survivors receiving chemotherapy. The study will be an experimental design in which the researchers have breast cancer survivors participate in one of the three different exercise programs. The researchers' main interest is in patient rated physical functioning and quality of life, which they will measure before and after the exercise programs by asking participants how they feel on various rating scales. The researchers will also measure their aerobic fitness on a treadmill and how strong they are by having them lift weights.
BACKGROUND: Aerobic exercise has been shown to improve physical fitness and quality of life
(QoL) in breast cancer survivors receiving chemotherapy but no study to date has examined
the addition of resistance exercise to aerobic exercise in this population. Resistance
exercise has proven to be an important adjunct to aerobic exercise in the cardiac
rehabilitation population although few trials have controlled for the total volume of
exercise.
PURPOSE: The primary purpose of the present trial is to compare the effects of a combined
aerobic and resistance exercise program (COMB) to a standard moderate volume of aerobic
exercise (STAN) and a higher volume of aerobic exercise (HIGH) that controls for the total
volume of exercise in the COMB arm.
METHODS: The study will be a prospective, three-armed, randomized controlled trial conducted
in Edmonton (coordinating center), Ottawa, and Vancouver. Participants will be 300 breast
cancer survivors scheduled to receive adjuvant chemotherapy. All three exercise groups will
be asked to perform supervised exercise 3 days/week for the length of their chemotherapy
treatment. The STAN group will be asked to perform approximately 500 kilocalories/week of
self-selected aerobic activities (e.g., treadmill, cycle ergometer, elliptical). This arm of
the trial is considered standard care based on the emerging consensus of recent systematic
reviews and recommendations from major cancer agencies. The HIGH group will be asked to
complete approximately 1,000 kilocalories/week of self-selected aerobic activities. The COMB
group will be asked to complete 1,000 kilocalories/week split equally between aerobic and
resistance exercise. The primary endpoint in the trial will be change in physical
functioning between baseline and post intervention as assessed by the physical functioning
subscale of the Short Form (SF) 36 scale. Secondary endpoints will include cardiorespiratory
fitness (maximal treadmill test), muscular strength (8 repetition maximum tests), muscular
endurance (standard load test at 50% of estimated baseline maximum), body composition (DEXA
scans), psychological distress, sleep quality, exercise adherence, and chemotherapy
completion rates.
RELEVANCE: An important issue for breast cancer survivors receiving chemotherapy is whether
there is any advantage to increasing the volume of aerobic exercise or adding resistance
exercise to a standard aerobic exercise program. If there is an advantage, then it is
important that breast cancer survivors receive this optimal exercise prescription to
maximize their ability to cope with their chemotherapy treatments and maintain their
physical function and QoL during this difficult time.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Recruiting |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |